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I. 
H-2  EFFECTS  ON  CELL-CELL INTERACTIONS  IN  THE 
RESPONSE  TO  SINGLE  NON-H-2  ALLOANTIGENS 
Donor H-2D  Region Control of H-7.1-Immunogenicity and Lack of 
Restriction In Vivo* 
BY PETER J. WETTSTEIN,$ GEOFFREY HAUGHTON,  AND JEFFREY A. FRELINGER 
(From the Department of  Microbiology, University of  Southern California School of  Medicine, Los 
Angeles, California 90033, and the Department of Bacteriology and Immunology, School of 
Medicine, University of North Carolina, Chapel Hill, North Carolina 27514) 
Immune response  (Ir)  1 genes  determine  the  ability  of hosts  to  respond 
immunologically to many antigens, including several cell surface antigens (1- 
3). The Ir control of the response to several non-H-2 histocompatibility antigens, 
including H-Y,  H-4,  and  H-7  has  been  documented (4-7).  Recent  evidence 
suggests a further role of genes in the H-2 complex in regulating the immuno- 
genicity, or rejectability, of H-Y-incompatible skin grafts  (8,  9),  presumably 
through regulation of H-Y antigen expression. 
A  considerable  number  of investigations  have  centered  on  the  study  of 
restriction of cell-mediated lympholysis with its apparent requirement for H-2 
compatibility of effectors and targets for efficient lympholysis. This phenomenon 
has been described in a  variety of responses,  including those to chemically- 
modified syngeneic cells (10, 11), virus-infected syngeneic cells (12, 13, reviewed 
in  14)  and,  most  important  to  our  studies,  non-H-2-histocompatibility  (H) 
antigens (15-17).  It has been suggested that H-2-1inked genes may alter the 
recognition (presentation) of non-H-2 H antigens by cytotoxic T cells (15). The 
subsequent demonstration of in  vivo cross-priming of F,  hybrid individuals 
with non-H-2-incompatible cells possessing either parental H-2 haplotype (18) 
suggested that such alteration probably was not the basis for restriction in the 
response to multiple non-H-2 H antigens. However, the complexity of the array 
of target  non-H-2  H  antigens  employed  in  these  studies  (18) limits  their 
usefulness for elucidation of the mechanism of H-2 restriction. 
We have performed a series of experiments employing skin grafting designed 
to examine the relevance of the in vitro restriction phenomenon to in vivo skin 
allograft rejection. To simplify the complexity of target non-H-2 H antigens we 
chose to study the response to a single alloantigen H-7.1 which has been shown 
to be under H-2-1inked Ir gene control (7,  19). In the experiments reported in 
this communication we have  (a)  examined the ability of H-7.1-incompatible 
* Supported by National Institutes of Health grant CA-16246 and American Cancer Society 
grant IM-90. 
$ Leukemia Society of America Postdoctoral Fellow. 
1  Abbreviations used in this paper: H, histocompatibility; Ir, immune response; MST,  median 
survival time. 
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TABLE  I 
Relevant  Genotypes  of Employed  Mouse  Strains 
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H-2 haplotype  origin of 
H-2  Strain  I  Ho 7 
Haplotype  K  S  G  D  T/a 
A  B  J  E  C 
C57BL/10  b  b  b  b  b  b  b  b  b  b  b  a 
B10.C-H-7  ~  b  b  b  b  b  b  b  b  b  b  b  b 
B10.A  a  k  k  k  k  k  d  d  d  d  a  a 
BIO-H-2°H-7  b  a  k  k  k  k  k  d  d  d  d  a  b 
B10.D2/o  d  d  d  d  d  d  d  d  d  d  c  a 
BIO-H-2~H-7 ~  d  d  d  d  d  d  d  d  d  d  c  b 
B10.A(1R)  M  k  k  k  k  k  d  d  *  b  b  a 
B10.A(2R)  h2  k  k  k  k  k  d  d  b  b  a 
B10.A(4R)  h4  k  k  b  b  b  b  b  b  b  b  a 
B10.A(SR)  /5  b  b  b  k  k  d  d  d  d  a  a 
B10.A(18R)  i/8  b  b  b  b  b  b  b  d  a  a 
B6-T/a °  b  b  b  b  b  b  b  b  b  b  a  a 
*  H-2G type presently  unknown;  therefore, crossover  position  has not been definitively  mapped to either side of H-2G. 
skin  grafts  possessing  a  single  parental  H-2  haplotype  to  cross-prime H-2 
heterozygous recipients for an accelerated second set rejection of H-7.1-incom- 
patible grafts with the opposing parental H-2 haplotype and (b) examined the 
effect of the  donor H-2-haplotype  on  the  ability  of H-7.1-incompatible  skin 
grafts to efficiently prime recipients. Extensive cross-priming with no evidence 
of restriction was observed. Further, the survival time of primary graf~s  and 
their priming efficiency depended upon the H-2 haplotype origin of donor genes 
in the H-2D region. 
Materials and Methods 
Mice.  The mice employed in this study and their respective genotypes are presented in Table 
I. Alleles at histocompatibility loci are indicated by superscript, lower case letters as dictated by 
genetic convention (20).  The antigenic specificities determined by these alleles are designated by 
corresponding arabic numerals following the locus designation (21); for example, the H-7  ~ and H- 
7 b  alleles  determine  the  H-7.1  and  H-7.2  antigens,  respectively.  C57BL/10ScSn,  B10.A/Sn, 
B10.D2/o Sn,  and B10.C(47N)/Sn  (referred to as B10.C-H-7 b) mice were derived from breeding 
stock generously provided by Dr. George D. Snell, The Jackson Laboratory, Bar Harbor, Maine, 
and  were  maintained  in  a  quarantined  production  facility.  The  B10.A(1R),  B10.A(4R),  and 
B10.A(5R)  strains  were  obtained  from  Dr.  Jack  Stimpfiing,  McLaughlin  Research  Institute, 
Great  Falls,  Mont.  B10.A(18R)  mice  were  kindly  supplied  by  Edward  Clark,  Department  of 
Microbiology and Immunology, University of California, Los Angeles, Calif.  B6-Tla a mice were 
bred  from  breeders  supplied  by  Dr.  Ron  Acton,  Department  of Microbiology,  University  of 
Alabama. The BIO-H-2aH-7  b and BIO-H-2~H-7  b strains were selected as described previously (7). 
These two strains differ from B10.A and B10.D2/o, respectively, at the H-7 locus. These congenic 
strain combinations define the H-7a'I-I-7  b allelic combination on the H-2 a and H-2 d backgrounds 
of B10.A and B10.D2/o as does the B10.C-H-7b:B10 combination on the background orB10 (22). 
Grafting  Technique.  Orthotopic  tail  skin  was  transplanted  to  6-  to  12-wk-old  recipients, 
according to the technique described previously (23).  Donors and recipients were sex-matched. 
Each recipient received one or two allografts from the same donor and one autograft. The grafts 
were  scored twice  a  week for the first  10  wk.  Grafts were  scored for healthy epithelial  scale 
pattern, pigment, and hair, and were scored rejected when no viable signs were observed. Graft 
survival times within a  sample population of recipients are  not distributed normally,  but are 1348  H-2D  CONTROL OF  H-7.1 IMMUNOGENICITY 
strongly skewed  to the right (24). Therefore, median survival times (MST) and 95% confidence 
limits were determined for each group of graft recipients. Calculations were made on an IBM 
1130 computer  (IBM  Corp.,  White  Plains,  N.  Y.)  through  the  use  of a  computer program 
employing probit transformation (25). The  program was  generously provided by  Dr.  Randy 
Adams, The Jackson Laboratory. Survival time distributions of different recipient groups were 
compared  by using the nonparametric Mann-Whitney U  Test  (26). A value of a  -<  0.01 was 
chosen to indicate a significant difference between two distributions. 
H-2 heterozygous recipients of primary H-7.1-incompatible  grafts possessing a single parental 
H-2 haplotype were grafted 14 days after initial graft rejection with secondary H-7.1-incompatible 
skin grafts from donors with either of the two parental H-2 haplotypes. Significant accelerated 
rejection of the  secondary graft possessing the  parental H-2  haplotype not shared  with the 
original graft donor was considered evidence of cross-priming. 
Results 
H-2  Determination  of Relative  Rejectability  of H-7.1-Incompatible  Skin 
Grafts.  Previously performed dominance testing has revealed that the fast 
response allele at the IrH-7.1  locus and associated with H.2 b is dominant over 
the slow response alleles associated with H-2 a and H-2 d  (19). These studies 
also suggested a  difference in the speed with which H-7.1-incompatible skin 
grafts from donors with different H-2 haplotypes were rejected by H-2 hetero- 
zygous recipients.  To test this possibility,  (BIO.C(H-2b)-H-7 a  ×  BIO-H-2dH  - 
7b)Fl  female recipients were graited with skin from either B10,  B10.D2,  or 
(B10 × B10.D2)F1 donors. The results of this experiment are presented in Table 
II. B10 and (B10  ×  B10.D2)F1  grai~ were rejected significantly more rapidly 
than B10.D2  grafts.  Similarly,  B10,  B10.A,  and  (B10.A  ×  B10)F1 skin was 
transplanted to (BIO.C(H-2b)-H-7 °  × BIO-H-2aH-7b)F~  male recipients. These 
results  are  presented  in  Table  III.  B10  and  (B10.A  ×  B10)FI  grafts  were 
rejected more rapidly than B10.A grafts. The results included in Tables II and 
III clearly demonstrate that (a) the H-2 genotype of donors of H-7.1-incompati- 
ble grafts determines their relative rejectability and (b) the allele determining 
greater rejectability is inherited as a dominant trait. 
In  Vivo Cross-Priming  by H-7.1-Incompatible  Skin Grafts Possessing Dis- 
tinct H-2 Haplotypes.  We tested the ability of H-7.1-incompatible skin grafts 
homozygous for a single parental H-2 haplotype to prime H-2 heterozygous F1 
recipients for accelerated rejection of secondary, H-7.1-imcompatible skin grafts 
homozygous for the  opposite parental H-2  haplotype.  (BIO.C(H-20)-H-7 b)  × 
BIO-H-2dH-7b)F~  recipients  of primary  B10,  B10.D2,  or  (B10  x  B10.D2)F~ 
grafts received secondary B10 and B10.D2 skin 14 days after their rejection of 
primary grafts. Hosts which did not reject primary grafts within 10 wk received 
secondary grafts 12 wk ai~r primary grafting. The results of these experiments 
are included in Table II. B10 primary grafts efficiently primed for the acceler- 
ated rejection of both B10 and B10.D2 secondary skin grafts. Further, primary 
B10 grafts were more effective in priming for accelerated rejection of B10.D2 
secondary grafts than were B10.D2 primary grafts. Not unexpectedly, secondary 
B10 grafts were rejected more rapidly than secondary B10.D2 graRs by recipi- 
ents  of primary  B10.D2  grafts.  A  similar  experiment was  conducted with 
(BIO.C(H-20)-H-7 ~  ×  BIO-H-2aH-7b)F~  recipients of primary B10,  B10.A,  or 
(B10.A  ×  B10)F~ grafts. The results of these experiments are shown in Table 
HI. Both primary B10 and B10.A grafts effectively primed for the rejection of 
secondary B10 grafts. Both B10 and B10.A skin cross-primed; however, second- P.  J.  WETTSTEIN,  G.  HAUGHTON,  AND  J.  A.  FRELINGER  1349 
TABLE  II 
The Survival Times of BlO, BIO.D2/o, and (B10  × B10.D2/o)F, Skin Grafts Transplanted to 
(B10.C-H-7 b × B10-H-2dH-7O)F, Female Recipients 
Primary  graft  do-  Secondary  Number  of re- 
nor  graft  donor  Recipient  cipients 
MST*  95% confidence  limits* 
Primary  Secondary  Primary  Secondary 
B10  -  (B10.C-H-7 #  x  13  23.94  -  21.70-26.25  - 
BIO-H-2eH-Tb)F, 
B10  B10  (B10.C-H-7 #  ×  13  -  9.52  6.23-12.39 
BIO.H-2dH.7#)F,'.t 
B10  B10.D2/o  (B10.C-H-7 b  x  13  -  9.73  -  8.68-10.78 
BIO-H-2'~H-7b)F,* 
B10.D2/o  -  (B10.C-H-7 #  ×  l0  61.95  -  54.95-68.96  - 
BIO-H.2dH-7b)F, 
B10.D2/o  B10  (B10.C-H-7 b  ×  10  -  17.50  -  11.34-23.73 
BIO.H-2dH-7b)F,* 
B10.D2/o  B10.D2/o  (B10.C-H-7 #  x  1O  -  28.77  -  23.24-34.37 
BIO-H.2eH-7#)F,, 
(B10  x  B10.D2/o)F,  -  (BIO.C-H-7  b x  6  34.63  26.95-43.05  - 
BIO.H.2#H.7#)F, 
(B10  x  B10.D2/o)F,  B10  (B10.C-H-7 #  x  6  -  10.50  -  10.50-10.50 
BIO.H-2dH-7b)F,$ 
(B10  x  B10.D2/o)F,  B10.D2/o  (B10.C-H-7 ~  x  6  -  12.53  -  9.24-15.82 
BIO-H-2eH-7b)F,* 
*  Expressed  in days. 
BI0  and  B10.D2/o  skin  grafted  to same  recipient  14 days  after  primary  graft  rejection. 
TABLE III 
The Survival Times of BlO, BIO.A, and (BlO,4  x BIO)F, Skin Grafts Transplanted to 
(BIO.C-H-7 b × BIO-H-2~H-7b)F,  Male Recipients 
Primary grai~do-  Secondary  Recipient  Number ofre- 
nor  graft  donor  cipients 
MST*  95% confidence  limits* 
Primary  Secondary  Primary  Secondary 
B10 
B10  B10 
B10  B10.A 
BI0.A 
BI0.A  BIO 
BI0.A  BIO.A 
(BI0 × BIO.A)F, 
(BI0 x BI0.A)F,  BI0 
(BI0 x BI0.A)F,  BIO.A 
(B10.C-H-7 b  x 
BIO-H-2"H-7#)F, 
BIO.C-H-7 b x 
BIO-H.2aH-Tb)F,$ 
B10.C-H-7 b  × 
BIO~I-2aH-7~)F,$ 
B10.C-H-7 b  x 
BIO.H-2.H-7~)F, 
B10.C-H-7 b  x 
BIO-H-2°H-7#)F,* 
B10.C-H-7 b  x 
BIO.H-2~H-7~)F,* 
B10.C-H-7 #  x 
BIO.H-2~H-7b)F, 
B10.C-H-7 b  x 
BIO-H-2aH-7b)F,* 
B10.C-H-7 #  x 
BIO-H-2"H-7b)F,* 
6  25.97  -  22.05-29.82  - 
6  -  10.08  -  8.61-11.55 
6  -  10.99  -  9.59-12.39 
8  56.28  -  50.12-62.37  - 
8  -  10.99  -  9.59-12.46 
8  -  21.84  -  17.71-26.04 
9  24.78  -  21.77-27.79  - 
9  -  9.73  -  8.33-11.06 
9  -  10,78  -  9.45-12.11 
* Expressed in  days. 
BI0 and BIO.A skin grafted to  same recipients  14 days after  primary graR rejection. 
ary  B10  grafts  were rejected more rapidly than  secondary B10.A  grafts  by 
recipients  of primary  B10.A  grafts.  Secondary B10  and  B10.A  grafts  were 
rejected with equal speed by recipients primed with B10 or (B10.A  ×  B10)F, 
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TABLE IV 
Intra-H-2 Mapping of Gene Determining Relative Rejectability of H- 
7.1-Incompatible Skin on (BIO.C-H-7 b x BIO-H-2aH-7b)F, Recipients 
Primary graft  Tertiary graft  Number of  MST*  95% confidence 
donor  donor  recipients  limits* 
B10  B10  4  8.755  2.87-14.63 
B10.A  4  11.34§  0.98-21.63 
B10.A(1R)  4  8.755  2.87-14.63 
B10.A(4R)  4  8.755  2.87-14.63 
B10.A(5R)  4  11.34§  0.98-21.63 
B10  9  8.755  3.43-14.00 
B10.A  9  16.24  13.37-19.11 
B10.A(1R)  9  8.755  3.43-14.00 
B10.A(4R)  9  8.755  3.43-14.00 
B10.A(5R)  9  20.37  17.29-23.52 
B10  7  8.755  3.29-14.21 
B10.A  7  33.25  28.42-38.08 
B10.A(1R)  7  8.755  3.29-14.21 
B10.A(4R)  7  8.755  3.29-14.21 
B10.A(5R)  6  21.56  14.14-28.98 
(BIO x BIO.A)F, 
BIO.A 
*  Expressed in days. 
$ All recipients rejected grafts at 10 days. 
§ Three of four recipients rejected grafts at 10 days. 
These results, therefore, show that in contrast to the expectations from in 
vitro observations of H-2 restriction, cross-priming for generation of cytotoxic 
effectors  occurs  very  efficiently in  vivo.  Further,  in  direct  contrast  to  the 
predictions of restriction, grafts bearing the H-2 b haplotype more efficiently 
primed for accelerated rejection of secondary grafts possessing the H-2 a or H- 
2 d haplotypes than did primary grafts from H-2 ~ or H-2 d donors. 
Mapping the Gene Governing Relative Rejectability.  [BIO.C(H-2b)-H-7  b  × 
B10-H-2 aH-7b]F, recipients of primary and secondary H-7.1-incompatible grafts 
(Table HI) received tertiary H-7.1-incompatible grafts donated by mice carrying 
H-2  haplotypes derived from H-2~/H-2 ~ recombinations. Tertiary skin grafts 
were donated by B10, B10.A,  B10.A(1R),  B10.A(4R),  and B10.A(5R) donors 20- 
27  wk  after  secondary  grafting.  The  survival  times  of tertiary  grafts  are 
presented in Table IV. B10 primary grafts were highly effective in accelerating 
the  rejection of all  tertiary  grafts  which were  rejected with  equal  MS~s. 
(B10.A  ×  B10)F,  primary grafts more effectively accelerated the rejection of 
B10,  B10.A(1R),  and B10.A(4R)  tertiary grafts than rejection of B10.A  (a  = 
0.01) and B10.A(5R)  (a <  0.01) tertiary grafts. Similarly, B10.A primary grafts 
more effectively accelerated the rejection of B10,  B10.A(1R),  and B10.A(4R) 
tertiary grafts than B10.A  (a  =  0.001) and B10.A(5R)  (a  =  0.02) secondary 
grafts. These results demonstrate that, as in the response to secondary grafts, 
B10 primary grafts prime for the accelerated rejection of B10.A tertiary grafts 
more  effectively than  B10.A  primary  grafts.  Further,  the  rejectability  of 
tertiary H-7.1-incompatible grafts is apparently determined by genes telomeric 
to the H-2 ht  recombination site. A more definitive mapping was achieved by 
grafting four tertiary graft recipients originally primed with (B10.A  x  B10)F, 
skin with skin from B10, B10.A, B10.A(1R), B10.A(2R), B10.A(5R), B10.A(18R), P.  J.  WETTSTEIN,  G.  HAUGHTON,  AND  J.  A.  FRELINGER 
TABLE  V 
Mapping of Gene Determining Relative Rejectability of H-7.1- 
Incompatible Grafts to the H-2D Region 
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Primary graft  Quaternary  Number of  MST*  95% confidence 
donor  graft donor  recipients  limits* 
(B10 x  B10.A)F1  B10  4  8.755  2.87-14.63 
B10.A  4  15.75§  9.87-21.63 
B10.A(1R)  4  8.755  2.87-14.63 
B10.A(2R)  4  8.755  2.87-14.63 
B10.A(5R)  4  15.75§  9.87-21.63 
B10.A(18R)  4  12.86  11.84-16.24 
B6-T/a a  4  8.755  2.87-14.63 
* Expressed in days. 
5 All recipients  rejected  grafts  at i0 days. 
§  All four recipients  rejected  grafts  at 17 days. 
and B6-Tla  a donors. The results  of  these transplants are shown in Table V. 
B10, B10.A(1R),  B10.A(2R),  and  B6-Tla"  quaternary grafts were rejected 
rapidly with equal MST's of 8.75 days. However,  B10.A, BI0.A(5R),  and 
B10.A(18R) quaternary grafts  were rejected  with significantly  lower MST's. 
Statistical  comparison of  distribution  of  grafts  donated by all  H-2D  b  and all  H- 
2D  d donors demonstrated that at the a  =  0.0001  level,  H-7.1-incompatible 
grafl~  from  H-2D b were rejected  more rapidly  than similar  grafts  from  H-2D  d 
donors. There was no difference  (a = 0.33)  between survival  times of  grafts 
from  H-2K b  and  H-2K  k  donors.  These  observations  are  consistent  with  mapping 
of the gene determining relative  rejectability  to the H-2D  region as it is 
defined  by the  H-2  hi,  H-2  h2,  and  H-2  ~8, recombination  sites  on the centromeric 
side  and the site  of  recombination  which resulted  in  the separation  of  the  H-2  a 
haplotype and Tla  ~ in the production  of  B6-T/a  e  on the telomeric  side. 
Discussion 
H-2-1inked Ir genes regulate  recipient  responsiveness to foreign non-H-2 
histocompatibility  antigens,  including  H-Y (4,  5),  H-4 (6),  and H-7 (7)  antigens. 
Of perhaps equal importance in the case  of  H-Y is the function  of  H-2-1inked 
genes in regulating the relative  rejectability  of  H-Y-incompatible skin grafts 
(8,  9).  In this  communication we have reported  similar  observations  in  demon- 
strating  that  the  relative  rejectability  of  H-7.1-incompatible  skin  grafts  depends 
upon the donor  H-2 genotype, specifically  the  H-2D genotype, of  the donor.  We 
have observed more recently  that the rejectability  of both H-4.2- and H-3.1- 
incompatible skin grafts  is controlled  by H-2-1inked genes (P. J. Wettstein, 
preliminary observations).  In both cases,  as in the case  of H-7.1, relatively 
high rejectability  associates  with the  H-2  b haplotype which cosegregates  with 
fast  responsiveness  to the respective  antigen in allograft  recipients.  Although 
the data  presented by Kralova and Demant (9)  demonstrate that  the rejectabil- 
ity of H-Y-incompatible skin grafts  is controlled  by an H-2-1inked gene, the 
variety  of  H-2 genotypes of  donors and recipients  do  not  allow  a definitive  intra- 
H-2 mapping of  the operative regulatory gene. We are presently  conducting 
experiments designed to determine the number, specificity, and intra-H-2 map 
positions of genes regulating rejectability of non-H-2-incompatible skin grafts. 1352  H-2D  CONTROL  OF  H-7.1  IMMUNOGENICITY 
It is particularly important to understand the basis for the effect of H-2D 
genes on H-7.1 antigenicity, as inferred from rejectability of H-7.1-incompatible 
skin grafts. Two plausible explanations come to mind. First, is the possibility 
that a gene in the H-2D region governs the surface density of H-7 molecules. 
That is, H-2D b epidermal cells would carry a high density of H-7 molecules and 
function as highly efficient stimulators of H-7-specific priming and cytotoxic 
effector generation in vivo and in vitro. The second possibility is that molecules 
determined  by  genes  in  the  H-2D  region  serve  as  interaction  structures, 
controlling the interactions of effectors with target cells as initial stimulators 
and/or secondarily as cytotoxic cell targets. Therefore, donor and recipient cells 
carrying complementary structures ceded for by genes associated with H-2Db 
would be expected to interact more efficiently than donor and recipient cells 
sharing H-2D d.  Differentiation between these two alternatives is experimen- 
tally possible. If differences in relative rejectability were due to quantitative 
differences in antigen density, then one would predict that the rejectability of 
donor cells would be dependent only upon donor H-2 genotype regardless of the 
H-2 genotype of the responding cells in vivo or in vitro. However, if rejectability 
differences  were  the  result  of  varying  efficiencies  of responder:donor  cell 
interactions, then the observed rejectability of donor cells would be dependent 
upon H-2 genotypes of both donor and recipient. One might envisage that such 
an interaction between responder and H-7-incompatible target cells is analogous 
to the preferential interaction between antigen-pulsed macrophages and specific 
subpopulations  of T  lymphocytes in  the  guinea  pig  (27). Experiments  are 
presently in progress to distinguish between these two possibilities with the 
use of a variety of donor:host combinations. 
The in vivo cross-priming reported in this communication has strong impli- 
cations for the study of restriction phenomena, particularly in the restricted 
cytolytic response to  non-H-2 histocompatibility antigens  (15, 17). Although 
cross-priming across multiple non-H-2 H barriers with cell injections has been 
observed in vivo (18), restriction dogma dictates that effectors subsequently 
generated from primed lymphocyte populations in vitro are H-2  restricted in 
their  cytotoxic activity.  The  results  reported  here  demonstrate that  H-7.1- 
incompatible skin grafts bearing a  single parental H-2  haplotype cross-prime 
H-2 heterozygous recipients for accelerated rejection of secondary H-7.1-incom- 
patible grafts bearing the opposite parental H-2 haplotype. Unlike the in vitro 
mixed lymphocyte culture of non-H-2-incompatible lymphocytes which results 
in  generation of H-2-restricted  cytotoxic lymphocytes, in vivo priming with 
non-H-2-incompatible skin grafts results in generation of cytotoxic lymphocytes, 
some of which appear to be unrestricted. The efficiency of in vivo cross-priming 
depends strongly upon the H-2  genotypes of the primary and secondary graft 
donor; matching of the primary and secondary graft H-2 genotypes is absolutely 
nonessential for accelerated rejection of secondary grafts. 
H-2 regulation of the ability of lymphocytes of cross-prime H-2 heterozygous 
recipients in vivo has not been reported although extensive cross-priming of 
precursors of cytotoxic effectors has been documented (18). This cross-priming 
resulted from immunization of (BALB/c × BALB.B)F, mice with challenges of 
B10.D2  and B10 cells. Such responses were probably specific for more than 30 
non-H-2 antigens as inferred from the estimation that BALB/c and C57BL/6 P.  J.  WETTSTEIN,  G.  HAUGHTON,  AND  J.  A.  FRELINGER  1353 
(closely related to B10) differ by more than 30 non-H-2 H  loci (28).  If different 
H-2  haplotypes  determine  relatively high  antigenicity  of different  subsets of 
non-H-2  H  antigens,  B10 and B10.D2 would be expected to prime  (BALB/c  × 
BALB.B)F1 recipients  preferentially  for different,  but only partially  overlap- 
ping,  subsets of non-H-2 H  antigens.  Limited cross-priming would result,  the 
extent of which would be dependent upon the degree of overlap between the 
subsets  of  H  antigens.  Interpretation  of  data  obtained  in  studies  of H-2 
restriction of non-H-2 H  antigen-specific cytolysis should include consideration 
of possible differential effects of  H-2 haplotypes on non-H-2 H antigenicity which 
may  mimic  actual  H-2  restriction.  Due  to  the  potential  importance  of an 
understanding  of H-2-controlled non-H-2 H  antigenicity,  we have undertaken 
an investigation into the differential effects of the H-2 b and H-2 ~ haplotypes on 
the antigenicity  of a  wide spectrum of non-H-2 H  antigens distinguishing  B6 
and BALB/c mice. 
In an accompanying communication we have described further investigations 
into the control of H-7.1 immunogenicity employing secondary mixed lympho- 
cyte culture and cell-mediated lympholysis. 
Summary 
Genes in the H-2 complex regulate the relative immunogenicity of the H-7.1 
histocompatibility alloantigen,  as measured by survival times of H-7.1-incom- 
patible skin grafts in vivo. The gene controlling relative rejectability of H-7.1- 
incompatible grafts has been mapped to the H-2D  region.  H-7.1-incompatible 
skin grafts donated by H-2D b donors were rejected significantly more rapidly 
by H-2 a/H-2 b heterozygous recipients  than  similar  H-7.1-incompatible  grafts 
donated by H-2D d donors.  Further,  there  was absolutely no evidence of H-2 
restriction in cytotoxic effector activity. In vivo cross-priming,  as indicated by 
accelerated  secondary graft  rejection,  was  extensive.  The  efficiency of cross- 
priming  was  dependent  upon  the  primary  and  secondary  graft  donor  H-2 
haplotypes. 
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